文献速递心境障碍

重性抑郁障碍的全代谢组特征

The metabolome-wide signature of major depressive disorder.
PubMed 文献 · Mol Psychiatry · 2024-06-07

在2770名荷兰临床队列受试者(1101例当前重性抑郁障碍、868例缓解期重性抑郁障碍、801名健康对照)中,使用全代谢组平台检测820种代谢物,基线时分别有139种和126种代谢物与当前重性抑郁障碍状态和抑郁严重程度相关,其中79种重叠,34种在6年随访数据中获得内部重复验证;下调代谢物富集于长链单不饱和脂肪酸和饱和脂肪酸,上调代谢物富集于溶血磷脂;孟德尔随机化分析提示遗传预测的溶血磷脂1-亚油酰-GPE(18:2)水平较高与抑郁风险增加相关。

要点

  • 基线时139种代谢物与当前重性抑郁障碍状态相关,126种与抑郁严重程度相关,79种重叠。
  • 重叠代谢物中34种在6年随访数据内部重复分析中得到确认。
  • 下调代谢物富集于长链单不饱和脂肪酸(P=6.7e-07)和饱和脂肪酸(P=3.2e-05),上调代谢物富集于溶血磷脂(P=3.4e-4)。

核心结论

  • 重性抑郁障碍的全代谢组特征表现为脂质代谢改变,即长链脂肪酸下调和溶血磷脂上调,遗传工具提示其可能具有因果参与。

研究设计与样本

  • 在来自大型荷兰临床队列的2770名受试者中,于基线使用全代谢组Metabolon平台检测820种代谢物,受试者包括1101例当前重性抑郁障碍、868例缓解期重性抑郁障碍和801名健康对照。
  • 在1805名受试者中于6年随访重复检测,包括327例当前重性抑郁障碍、1045例缓解期重性抑郁障碍和433名健康对照。
  • 重性抑郁障碍诊断基于DSM-IV精神科访谈,抑郁严重程度采用抑郁症状自评量表(Inventory of Depressive Symptomatology Self-report)测量。
  • 在基线和6年随访时评估代谢物与重性抑郁障碍状态及抑郁严重程度的关联。
  • 孟德尔随机化分析使用代谢物(N=14,000)和重性抑郁障碍(N=800,000)的遗传工具。

主要发现

  • 基线时,分别有139种和126种代谢物与当前重性抑郁障碍状态和抑郁严重程度相关,其中79种重叠。
  • 在模型中加入体重指数和降脂药物后,结果仅轻微改变。
  • 重叠代谢物中,34种在使用6年随访数据的内部重复分析中得到确认。
  • 下调代谢物富集于长链单不饱和脂肪酸(P=6.7e-07)和饱和脂肪酸(P=3.2e-05);上调代谢物富集于溶血磷脂(P=3.4e-4)。
  • 孟德尔随机化分析显示,遗传预测的溶血磷脂1-亚油酰-GPE(18:2)水平较高与抑郁风险增加相关。

关键数值与推荐

  • 重性抑郁障碍诊断基于DSM-IV精神科访谈。
  • 抑郁严重程度采用抑郁症状自评量表(Inventory of Depressive Symptomatology Self-report)测量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Major Depressive Disorder (MDD) is a common, frequently chronic condition characterized by substantial molecular alterations and pathway dysregulations. Single metabolite and targeted metabolomics platforms have revealed several metabolic alterations in depression, including energy metabolism, neurotransmission, and lipid metabolism. More comprehensive coverage of the metabolome is needed to further specify metabolic dysregulations in depression and reveal previously untargeted mechanisms. Here, we measured 820 metabolites using the metabolome-wide Metabolon platform in 2770 subjects from a large Dutch clinical cohort with extensive clinical phenotyping (1101 current MDD, 868 remitted MDD, 801 healthy controls) at baseline, which were repeated in 1805 subjects at 6-year follow up (327 current MDD, 1045 remitted MDD, 433 healthy controls). MDD diagnosis was based on DSM-IV psychiatric interviews. Depression severity was measured with the Inventory of Depressive Symptomatology Self-report. Associations between metabolites and MDD status and depression severity were assessed at baseline and at 6-year follow-up. At baseline, 139 and 126 metabolites were associated with current MDD status and depression severity, respectively, with 79 overlapping metabolites. Adding body mass index and lipid-lowering medication to the models changed results only marginally. Among the overlapping metabolites, 34 were confirmed in internal replication analyses using 6-year follow-up data. Downregulated metabolites were enriched with long-chain monounsaturated (P = 6.7e-07) and saturated (P = 3.2e-05) fatty acids; upregulated metabolites were enriched with lysophospholipids (P = 3.4e-4). Mendelian randomization analyses using genetic instruments for metabolites (N = 14,000) and MDD (N = 800,000) showed that genetically predicted higher levels of the lysophospholipid 1-linoleoyl-GPE (18:2) were associated with greater risk of depression. The identified metabolome-wide profile of depression indicated altered lipid metabolism with downregulation of long-chain fatty acids and upregulation of lysophospholipids, for which causal involvement was suggested using genetic tools. This metabolomics signature offers a window on depression pathophysiology and a potential access point for the development of novel therapeutic approaches.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Jansen R, Milaneschi Y, Schranner D, et al. The metabolome-wide signature of major depressive disorder. Mol Psychiatry. 2024. PMID: 38849517. doi:10.1038/s41380-024-02613-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。